Supplementary Tables and Legends from Circulating Tumor Cells with Aberrant <i>ALK</i> Copy Number Predict Progression-Free Survival during Crizotinib Treatment in <i>ALK</i>-Rearranged Non–Small Cell Lung Cancer Patients

Supplementary data including: the legend for Supplementary Figure 1 the Supplementary Table 1 entitled detection of ALK-rearrangement and ALK copy number gain in tumors and CTC of ALK-rearranged patients the Supplementary Table 2 entitled descriptive statistics of numbers of CTC in ALK-rearranged patients at baseline and under crizotinib therapy the Supplementary Table 3 entitled levels of significant association between CTC subsets and clinical parameters at baseline the Supplementary Table 4 entitled successive treatment lines received post-crizotinib